Refine your search:     
Report No.
 - 

Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of $$^{186}$$Re-MAG3-conjugated bisphosphonate ($$^{186}$$Re-MAG3-HBP), an agent for treatment of painful bone metastases

Ogawa, Kazuma*; Mukai, Takahiro*; Kawai, Keiichi*; Takamura, Norito*; Hanaoka, Hirofumi*; Hashimoto, Kazuyuki; Shiba, Kazuhiro*; Mori, Hirofumi*; Saji, Hideo*

We have developed a $$^{186}$$Re-MAG3 complex-conjugated bisphosphonate ($$^{186}$$Re-MAG3-HBP) for the treatment of painful bone metastases. We assumed competitive inhibitors of protein binding to be useful for procuring a favorable biodistribution of $$^{186}$$Re-MAG3-HBP because it has been reported that the concurrent administration of $$^{rm 99m}$$Tc-MAG3 and drugs with high affinity for serum protein enhanced total clearance and tissue distribution. The protein binding of $$^{186}$$Re-MAG3-HBP in a human serum albumin solution was significantly decreased by the addition of ceftriaxone. In the biodistribution experiments, pretreatment with ceftriaxone enhanced the clearance of the radioactivity of $$^{186}$$Re-MAG3-HBP in blood and nontarget tissues but had no effect on accumulation in bone. The findings suggested that the use of protein-binding competitive inhibitors would be effective in improving the pharmacokinetics of radiopharmaceuticals with high affinity for serum protein.

Accesses

:

- Accesses

InCites™

:

Percentile:42.34

Category:Radiology, Nuclear Medicine & Medical Imaging

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.